LYMPERIS EMMANOUIL-INRASTES - Official Web Site

LYMPERIS
EMMANOUIL

Phd Candidate, Chemist

Download CV

ENGLISH

Lab: Molecular Radiopharmacy

LYMPERIS EMMANOUIL

PhD candidate

Laboratory Research Assistant, Molecular Radiopharmacy, INRASTES, NCSR “Demokritos”

Research interests

Emmanouil Lymperis is a chemist, holding a master degree in organic synthesis, and is a PhD candidate in the Department of Pharmacy at the Aristotle University of Thessaloniki. The PhD Thesis is implemented at the National Center for Research in Natural Sciences “Demokritos”, under the supervision of Dr. Berthold Nock. Mr. Lymperis has worked as a scientific associate with a fixed-term contract in Molecular Radiopharmacy, INRASTES, NCSR “Demokritos”, in collaboration with the Department of Nuclear Medicine of Erasmus MC, University of Rotterdam, Rotterdam, The Netherlands, with research aiming at the development and evaluation of radiolabelled peptides applied in oncology. He was member of the research team, which in 2013 in collaboration with Erasmus MC, received the prestigious “Marie Curie Award” (https://www.eanm.org/congresses-events/awards-grants/winners/) for their work on the “in situ” stabilization of radiopeptides in vivo by co-administration of key-protease inhibitors.

Education and Certifications

Present PhD Candidate, Department of Pharmacy, Aristotle University of Thessaloniki in collaboration with the National Center for Research in Natural Sciences “Demokritos”.

2010 Master Diploma in Organic Synthesis, Department of Chemistry, Aristotle University of Thessaloniki.

2008 1st study cycle of Oenology, University of Bordeaux 2, France.

2007 Degree in Chemistry, Department of Chemistry, Aristotle University of Thessaloniki.

Professional and Research Experience

Present Chemist, HELLENIC PETROLEUM SA, Elefsis Industrial Plant, Department of Chemistry.

» Laboratory Associate, Molecular Radiopharmaceutical, INRASTES, NCSR “Demokritos”.

2012-2015 Scientific Associate, Molecular Radiopharmaceuticals, INRASTES, NCSR “Demokritos”.

2011-2012 Professor, SCE Akmi, with subject the Drug Control Methods

Publications in international journals with judges: 11

(https://pubmed.ncbi.nlm.nih.gov/?term=Lymperis+E&sort=date)

Selected Publications

Lymperis, E., Kaloudi, A., Sallegger, W., Bakker, I.L., Krenning, E.P., De Jong, M., Maina, T. and Nock, B.A., Radiometal-Dependent Biological Profile of the Radiolabeled Gastrin-Releasing Peptide Receptor Antagonist SB3 in Cancer Theranostics: Metabolic and Biodistribution Patterns Defined by Neprilysin Bioconjugate Chemistry, Volume 29, Pages: 1774-1784, 2018 [doi]

Kanellopoulos, P., Lymperis, E., Kaloudi, A., de Jong, M., Krenning, E.P., Nock, B.A. and Maina, T., [99mTc]Tc-DB1 mimics with different-length PEG spacers: Preclinical comparison in GRPR-positive models Molecules, Volume 25, 2020 [doi]

Lymperis, E., Kaloudi, A., Kanellopoulos, P., Krenning, E.P., de Jong, M., Maina, T. and Nock, B.A., Comparative evaluation of the new GRPR-antagonist 111In-SB9 and 111In-AMBA in prostate cancer models: Implications of in vivo stability Journal of Labelled Compounds and Radiopharmaceuticals, Volume 62, Pages: 646-655, 2019 [doi]

Lymperis, E., Kaloudi, A., Kanellopoulos, P., De Jong, M., Krenning, E.P., Nock, B.A. and Maina, T., Comparing Gly11/Dala11-Replacement vs. The in-situ neprilysin-inhibition approach on the tumor-targeting efficacy of the 111In-SB3/111In-SB4 Radiotracer Pair Molecules, Volume 24, 2019 [doi]

Kaloudi, A., Lymperis, E., Giarika, A., Dalm, S., Orlandi, F., Barbato, D., Tedesco, M., Maina, T., De Jong, M. and Nock, B.A., NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor-Bearing Mice Molecules, Volume 22, 2017 [doi]

Selected Grants

Phase I clinical trial using a novel CCK-2/gastrin receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma

2013-2016 | ΕΣΠΑ-ERANET

The research project “Phase I clinical trial using a novel CCK-2/gastrin receptor-localizing radiolabelled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma” coded ERANET TRANSCAN-GRAN-T-MTC (Ε11820) with a 3-year duration (20...

(Radio)diagnostic - (Radio)therapeutic Peptides and Peptide-like Molecules for Use in Oncology

2007-2014 | EMC, Rotterdam/Biosynthema Lt MO/USA

The research project “(Radio)diagnostic - (Radio)therapeutic Peptides and Peptide-like Molecules for Use in Oncology” coded Ε11461 with a 7-year duration (2007-2014) is coordinated by B. A. Nock. It concerns a research cooperation of the Molecular Radiopharmacy team with the Department of Nuclear Me...